Emerging treatment options for the management of brain metastases in patients with HER2-positive metastatic breast cancer

by Chien, A. Jo, Rugo, Hope S.
Published 2012

The impact of 5-hydroxytryptamine-receptor antagonists on chemotherapy treatment adherence, treatment delay, and nausea and vomiting

by Palli, Swetha Rao, Grabner, Michael, Quimbo, Ralph A, Rugo, Hope S
Published 2015

A Review of NEPA, a Novel Fixed Antiemetic Combination with the Potential for Enhancing Guideline Adherence and Improving Control of Chemotherapy-Induced Nausea and Vomiting

by Hesketh, Paul J., Aapro, Matti, Jordan, Karin, Schwartzberg, Lee, Bosnjak, Snezana, Rugo, Hope
Published 2015

Pharmacogenetic testing affects choice of therapy among women considering tamoxifen treatment

by Lorizio, Wendy, Rugo, Hope, Beattie, Mary S, Tchu, Simone, Melese, Teri, Melisko, Michelle, Wu, Alan HB, Lawrence, H Jeffrey, Nikoloff, Michele, Ziv, Elad
Published 2011

A randomized, phase II, three-arm study of two schedules of ixabepilone or paclitaxel plus bevacizumab as first-line therapy for metastatic breast cancer

by Rugo, Hope S., Campone, Mario, Amadori, Dino, Aldrighetti, Daniela, Conte, PierFranco, Wardley, Andrew, Villanueva, Cristian, Melisko, Michelle, McHenry, M. Brent, Liu, David, Lee, Francis, Pivot, Xavier
Published 2013

Treatment patterns and clinical outcomes in elderly patients with HER2-positive metastatic breast cancer from the registHER observational study

by Kaufman, Peter A., Brufsky, Adam M., Mayer, Musa, Rugo, Hope S., Tripathy, Debu, Yood, Marianne Ulcickas, Feng, Shibao, Wang, Lisa I., Quah, Cheng S., Yardley, Denise A.
Published 2012

The SystHERs registry: an observational cohort study of treatment patterns and outcomes in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer...

by Tripathy, Debu, Rugo, Hope S, Kaufman, Peter A, Swain, Sandra, O’Shaughnessy, Joyce, Jahanzeb, Mohammad, Mason, Ginny, Beattie, Mary, Yoo, Bongin, Lai, Catherine, Masaquel, Anthony, Hurvitz, Sara
Published 2014

Racial disparities in treatment patterns and clinical outcomes in patients with HER2-positive metastatic breast cancer

by Rugo, Hope S., Brufsky, Adam M., Yood, Marianne Ulcickas, Tripathy, Debu, Kaufman, Peter A., Mayer, Musa, Yoo, Bongin, Abidoye, Oyewale O., Yardley, Denise A.
Published 2013

Treatment patterns and clinical outcomes for patients with de novo versus recurrent HER2-positive metastatic breast cancer

by Yardley, Denise A., Kaufman, Peter A., Brufsky, Adam, Yood, Marianne Ulcickas, Rugo, Hope, Mayer, Musa, Quah, Cheng, Yoo, Bongin, Tripathy, Debu
Published 2014

A Novel Strategy for Detection and Enumeration of Circulating Rare Cell Populations in Metastatic Cancer Patients Using Automated Microfluidic Filtration and Multiplex Immunoassay

by Magbanua, Mark Jesus M., Pugia, Michael, Lee, Jin Sun, Jabon, Marc, Wang, Victoria, Gubens, Matthew, Marfurt, Karen, Pence, Julia, Sidhu, Harwinder, Uzgiris, Arejas, Rugo, Hope S., Park, John W.
Published 2015

A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer

by Rugo, Hope S., Jo Chien, A., Franco, Sandra X., Stopeck, Alison T., Glencer, Alexa, Lahiri, Soumi, Arbushites, Michael C., Scott, Janet, Park, John W., Hudis, Clifford, Nulsen, Ben, Dickler, Maura N.
Published 2011

Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Compreh...

by Vaz-Luis, Ines, Ottesen, Rebecca A, Hughes, Melissa E, Marcom, P Kelly, Moy, Beverly, Rugo, Hope S, Theriault, Richard L, Wilson, John, Niland, Joyce C, Weeks, Jane C, Lin, Nancy U
Published 2012

Oral mucosal injury caused by mammalian target of rapamycin inhibitors: emerging perspectives on pathobiology and impact on clinical practice

by Peterson, Douglas E., O'Shaughnessy, Joyce A., Rugo, Hope S., Elad, Sharon, Schubert, Mark M., Viet, Chi T., Campbell‐Baird, Cynthia, Hronek, Jan, Seery, Virginia, Divers, Josephine, Glaspy, John, Schmidt, Brian L., Meiller, Timothy F.
Published 2016

Utility of patient-derived lymphoblastoid cell lines as an ex vivo capecitabine sensitivity prediction model for breast cancer patients

by Morrison, Gladys, Lenkala, Divya, LaCroix, Bonnie, Ziliak, Dana, Abramson, Vandana, Morrow, Phuong Khanh, Forero, Andres, Van Poznak, Catherine, Rugo, Hope S, Nanda, Rita, O'Donnell, Peter H., Huang, R. Stephanie
Published 2016

Serial expression analysis of breast tumors during neoadjuvant chemotherapy reveals changes in cell cycle and immune pathways associated with recurrence and response

by Magbanua, Mark Jesus M., Wolf, Denise M., Yau, Christina, Davis, Sarah E., Crothers, Julia, Au, Alfred, Haqq, Christopher M., Livasy, Chad, Rugo, Hope S., Esserman, Laura, Park, John W., van ’t Veer, Laura J.
Published 2015

Assessing the discordance rate between local and central HER2 testing in women with locally determined HER2-negative breast cancer

by Kaufman, Peter A, Bloom, Kenneth J, Burris, Howard, Gralow, Julie R, Mayer, Musa, Pegram, Mark, Rugo, Hope S, Swain, Sandra M, Yardley, Denise A, Chau, Miu, Lalla, Deepa, Yoo, Bongin, Brammer, Melissa G, Vogel, Charles L
Published 2014

Safety and tolerability of etirinotecan pegol in advanced breast cancer: analysis of the randomized, phase 3 BEACON trial

by Cortés, Javier, Rugo, Hope S., Twelves, Chris, Awada, Ahmad, Perez, Edith A., Im, Seock-Ah, Zhao, Carol, Hoch, Ute, Tomkinson, Denise, Buchanan, James, Tagliaferri, Mary, Hannah, Alison, O’Shaughnessy, Joyce
Published 2016

Everolimus plus exemestane as first-line therapy in HR+, HER2− advanced breast cancer in BOLERO-2

by Beck, J. Thaddeus, Hortobagyi, Gabriel N., Campone, Mario, Lebrun, Fabienne, Deleu, Ines, Rugo, Hope S., Pistilli, Barbara, Masuda, Norikazu, Hart, Lowell, Melichar, Bohuslav, Dakhil, Shaker, Geberth, Matthias, Nunzi, Martina, Heng, Daniel Y. C., Brechenmacher, Thomas, El-Hashimy, Mona, Douma, Shyanne, Ringeisen, Francois, Piccart, Martine
Published 2013

Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis

by Yardley, Denise A., Noguchi, Shinzaburo, Pritchard, Kathleen I., Burris, Howard A., Baselga, José, Gnant, Michael, Hortobagyi, Gabriel N., Campone, Mario, Pistilli, Barbara, Piccart, Martine, Melichar, Bohuslav, Petrakova, Katarina, Arena, Francis P., Erdkamp, Frans, Harb, Wael A., Feng, Wentao, Cahana, Ayelet, Taran, Tetiana, Lebwohl, David, Rugo, Hope S.
Published 2013

Erratum to: Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis

by Yardley, Denise A., Noguchi, Shinzaburo, Pritchard, Kathleen I., Burris, Howard A., Baselga, José, Gnant, Michael, Hortobagyi, Gabriel N., Campone, Mario, Pistilli, Barbara, Piccart, Martine, Melichar, Bohuslav, Petrakova, Katarina, Arena, Francis P., Erdkamp, Frans, Harb, Wael A., Feng, Wentao, Cahana, Ayelet, Taran, Tetiana, Lebwohl, David, Rugo, Hope S.
Published 2014